• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Attorney general to investigate opioid marketing practices

Attorney general to investigate opioid marketing practices

October 1, 2015
CenterWatch Staff

Attorney General Joseph Foster has launched an investigation into the manner in which several pharmaceutical companies have marketed prescription opioids in New Hampshire.

The investigation was started after review of preliminary information indicated that drug companies may have deceptively minimized the risk of addiction from long-term use of narcotic painkillers and exaggerated their benefits for treating chronic pain. If supported, allegations of such fraudulent marketing could have misled doctors and patients and prevented them from making informed decisions about whether, when and how to use the drugs and might have caused the state to pay for potentially dangerous and unnecessary opioid prescriptions.

“As is evident to medical professionals, law enforcement and families across the state, we have an opioid crisis in which overprescribing of opioids has created a corresponding wave of abuse, diversion and addiction, with tragic results for individual patients, their loved ones and communities,” said Foster. “The increased and widespread use, abuse and misuse of opioids has had a corresponding impact on the rise of the use of heroin, to which users turn when they can no longer obtain or afford prescription drugs. The cost in individual suffering and to healthcare and law enforcement has been, quite simply, overwhelming. We have a responsibility to understand and address its causes.”

Foster’s office is involved in many aspects of the opioid crisis in New Hampshire and currently is working with a committee established by the governor to present revised rules to the New Hampshire Board of Medicine with the goal of adopting protocols that all practitioners must follow when prescribing opioids.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing